Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, when a causative role of the drug is implausible, suggested stepped-up ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

How Genetic Factors Are Associated with Behavioral Side Effects of GLP-1 Weight Loss Medication Glucagon-like peptide 1 ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.

In the largest study of its kind, scientists have mapped out the ample health benefits of drugs like Ozempic and Wegovy, many ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Where can researchers look for a beacon of hope amid trying times in the pharmaceutical industry? Read on for answers.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Media maven Oprah Winfrey stirred controversy during a recent “The Oprah Podcast” episode with Yale University obesity medicine physician Dr.